JN Medsys introduces new generation digital PCR system with greater sensitivity and the highest detection throughput
Singapore, 1 December 2017 – JN Medsys, a life science company behind the high-throughput chip-based Clarity™ digital PCR system, today announced the launch of a new generation digital PCR system. The new system is capable of generating more than 40,000 partitions per reaction and features 4- to 6-colour detection channels to allow simultaneous detection of more targets in a single reaction.
Targeting users that demand greater performance, the new system offers better specifications over the Clarity™ system, which is the first digital PCR product commercialised by the company. The new system, named the Clarity™ Plus+, features improved consumables that now provides at least 4 times more partitions than the Clarity™. It uses ultra-high density chips that can consistently generate more than 40,000 partitions per reaction, to provide greater dynamic range and better accuracy in the absolute quantitation of nucleic acids, particularly rare targets. The increase in partitions is designed around the same chip footprint, meaning that the new tube-strips still fit conventional thermal cyclers to allow up to 96 reactions per digital PCR run as before. The new system also retains many features of the Clarity™ system which minimizes the risk of contamination, dead volume and significant sample loss that may be seen in other systems.
The new system also comes with a more powerful Reader equipped with a 4- to 6-colour detection system to increase the detection throughput in digital PCR. With multiplexed detection of 4-6 targets per reaction and with up to 96 reactions per run, the system can now provide detection of up to 384 or 576 different targets in each digital PCR experiment. With these improvements, the new system pushes the limits of digital PCR analysis by providing better dynamic range and accuracy, and possibly the highest detection throughput.
“To tackle increasingly demanding applications such as in liquid biopsy, more powerful digital PCR systems capable of better performances are required.” says Dr Johnson Ng, founder and CEO of JN Medsys. “By increasing the number of partitions to more than 40,000 in each reaction, the new system is able to analyse samples over a wider dynamic range of concentrations. More importantly, rare mutations or low abundance targets can be detected with greater sensitivity by reducing competition from different primer and probe sets in multiplex assays. In addition, the new system will have detection throughput comparable to most real-time PCR systems. We are truly excited by the possibilities provided by this new system.” Dr Ng added.
JN Medsys will unveil the new digital PCR system at the qPCR and Digital PCR Congress in London, UK. The new system will be made available to early users in the second quarter of 2018.
For more information on JN Medsys or its ClarityTM digital PCR system, please contact us at email@example.com.
About JN Medsys
JN Medsys is a commercial stage life science company seeking to empower precision diagnostics through its Clarity digital polymerase chain reaction (PCR) platform. The Clarity digital PCR is the only system in the world that features a proprietary high-resolution chip partitioning technology. This provides unprecedented throughput, sensitivity and precision for nucleic acids detection especially in liquid biopsy. Our aim is to make better digital PCR systems that have the best-in-class specifications to achieve superior performance that can be used across a broad spectrum of applications. We aim to achieve widespread use of digital PCR, and firmly believe that digital PCR can one day replace qPCR.